유도만능줄기세포 생산 시장 규모, 점유율, 성장 분석 : 프로세스별, 워크플로우별, 제품별, 용도별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)
Induced Pluripotent Stem Cells Production Market Size, Share, and Growth Analysis, By Process (Manual, Automated), By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End-Use, By Region - Industry Forecast 2025-2032
상품코드:1687538
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 03월
페이지 정보:영문 219 Pages
라이선스 & 가격 (부가세 별도)
한글목차
유도만능줄기세포 생산 시장 규모는 2023년에 15억 3,000만 달러로, 2024년 16억 8,000만 달러에서 2032년에는 34억 9,000만 달러로 확대하며, 예측 기간(2025-2032년)의 CAGR은 9.6%로 성장할 전망입니다.
줄기세포(iPSC) 제조 시장은 재생의료 및 세포치료 분야에서 괄목할 만한 성장과 혁신을 이루고 있습니다. 성체 세포에서 유도되어 다능성 상태로 재프로그래밍된 iPSC는 개인 맞춤형 치료와 질병 모델링에 큰 잠재력을 제공합니다. 이 급성장하는 시장은 신약개발과 다양한 질환에 대한 iPSC의 적용에 대한 이해도가 높아짐에 따라 성장하고 있습니다. R&D 및 생명공학 기업은 확장 가능하고 비용 효율적인 iPSC 생산을 위한 효율적인 기술을 적극적으로 개발하고 있습니다. 학계, 산업계, 의료기관의 협업이 진보를 촉진하는 한편, 엄격한 규제 프레임워크와 윤리적 고려사항은 표준화된 방법론의 필요성을 강조하는 환경을 조성하고 있습니다. 세계 헬스케어의 발전과 함께 iPS 세포 제조 시장은 지속적으로 확대될 것이며, 과학적 혁신과 치료 솔루션의 길을 열어줄 것입니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
규제 상황
유도만능줄기세포 생산 시장 규모 : 프로세스별 & CAGR(2025-2032)
시장 개요
매뉴얼
자동화
유도만능줄기세포 생산 시장 규모 : 워크플로우별 & CAGR(2025-2032)
시장 개요
재프로그래밍
세포배양
유도만능줄기세포 생산 시장 규모 : 제품별 & CAGR(2025-2032)
시장 개요
소모품과 키트
기기
서비스
유도만능줄기세포 생산 시장 규모 : 용도별 & CAGR(2025-2032)
시장 개요
의약품 개발과 발견
재생의료
독성학 연구
질환 모델
기타
유도만능줄기세포 생산 시장 규모 : 최종 용도별 & CAGR(2025-2032)
시장 개요
학술 조사기관
바이오테크놀러지·제약회사
병원·클리닉
유도만능줄기세포 생산 시장 규모 : 지역별 & CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
FUJIFILM Cellular Dynamics(USA)
Astellas Pharma(Japan)
Thermo Fisher Scientific(USA)
Takara Bio(Japan)
Lonza Group(Switzerland)
Merck KGaA(Germany)
ReproCELL(Japan)
STEMCELL Technologies(Canada)
Fate Therapeutics(USA)
Cynata Therapeutics(Australia)
Axol Bioscience(UK)
Ncardia(Belgium)
Pluricell Biotech(Brazil)
Evotec(Germany)
BioTime(USA)
Cellular Engineering Technologies(USA)
StemoniX(USA)
BrainXell(USA)
EMD Millipore(USA)
R&D Systems(USA)
결론과 제안
KSA
영문 목차
영문목차
Induced Pluripotent Stem Cells Production Market size was valued at USD 1.53 billion in 2023 and is poised to grow from USD 1.68 billion in 2024 to USD 3.49 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).
The triggered pluripotent stem cell (iPSC) manufacturing market is experiencing remarkable growth and innovation within regenerative medicine and cellular therapy. Derived from adult cells and reprogrammed into a pluripotent state, iPSCs offer significant potential for personalized treatments and disease modeling. This burgeoning market is fueled by an increasing understanding of iPSCs' applications in drug discovery and various medical conditions. Researchers and biotech firms are actively developing efficient techniques for scalable and cost-effective iPSC production. Collaborations among academia, industry, and healthcare institutions are driving advancements, while stringent regulatory frameworks and ethical considerations shape the landscape, highlighting the need for standardized practices. As global healthcare evolves, the iPSC manufacturing market is set for continued expansion, paving the way for scientific breakthroughs and therapeutic solutions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Induced Pluripotent Stem Cells Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Induced Pluripotent Stem Cells Production Market Segments Analysis
Global Induced Pluripotent Stem Cells Production Market is segmented by Process, Workflow, Product, Application, End-Use and region. Based on Process, the market is segmented into Manual and Automated. Based on Workflow, the market is segmented into Reprogramming and Cell Culture. Based on Product, the market is segmented into Consumables & Kits, Instruments and Services. Based on Application, the market is segmented into Drug Development & Discovery, Regenerative Medicine, Toxicology Studies, Disease Modeling and Others. Based on End-Use, the market is segmented into Academic & Research Institutes, Biotechnology & Pharmaceutical Companies and Hospitals & Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Induced Pluripotent Stem Cells Production Market
A significant driving force behind the global induced pluripotent stem cells (iPSC) production market is the ongoing advancements in regenerative medicine. These stem cells present substantial potential for creating personalized and effective treatments for various medical conditions, thereby attracting significant investment in research and development. Such innovations not only broaden the applications of iPSCs but also present novel therapeutic options, which significantly propel market growth. The increasing interest from pharmaceutical companies and healthcare institutions further enhances this trend, underscoring the pivotal role that advancements in regenerative medicine play in fostering market expansion and stimulating continued investment in iPSC technologies.
Restraints in the Induced Pluripotent Stem Cells Production Market
One significant constraint facing the global induced pluripotent stem cells (iPSC) production market is the array of ethical and regulatory hurdles. Issues regarding the use of human-derived materials, coupled with concerns about the potential misuse of iPSC technology, have led to the implementation of strict regulations in various regions. These obstacles can impede research initiatives, raise compliance costs, and generate market uncertainty. Consequently, such factors can hinder the pace of iPSC adoption and commercialization, ultimately affecting the growth and development of this promising sector in regenerative medicine and biotechnology.
Market Trends of the Induced Pluripotent Stem Cells Production Market
The global Induced Pluripotent Stem Cells (iPSC) production market is witnessing a significant trend driven by the emergence of iPSC-based disease modeling. Researchers and pharmaceutical companies are increasingly leveraging iPSC technology to develop disease-specific cell lines, facilitating more accurate and personalized modeling of a variety of diseases, including genetic disorders, neurodegenerative conditions, and cardiovascular diseases. This shift not only enhances drug discovery and development processes but also fosters the emergence of targeted and effective therapeutic strategies, ultimately shaping the future landscape of precision medicine. As a result, the demand for iPSC products is expected to surge, propelling market growth in the coming years.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Global Induced Pluripotent Stem Cells Production Market Size by Process & CAGR (2025-2032)
Market Overview
Manual
Automated
Global Induced Pluripotent Stem Cells Production Market Size by Workflow & CAGR (2025-2032)
Market Overview
Reprogramming
Cell Culture
Global Induced Pluripotent Stem Cells Production Market Size by Product & CAGR (2025-2032)
Market Overview
Consumables & Kits
Instruments
Services
Global Induced Pluripotent Stem Cells Production Market Size by Application & CAGR (2025-2032)
Market Overview
Drug Development & Discovery
Regenerative Medicine
Toxicology Studies
Disease Modeling
Others
Global Induced Pluripotent Stem Cells Production Market Size by End-Use & CAGR (2025-2032)
Market Overview
Academic & Research Institutes
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics
Global Induced Pluripotent Stem Cells Production Market Size & CAGR (2025-2032)
North America (Process, Workflow, Product, Application, End-Use)
US
Canada
Europe (Process, Workflow, Product, Application, End-Use)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Process, Workflow, Product, Application, End-Use)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Process, Workflow, Product, Application, End-Use)
Brazil
Rest of Latin America
Middle East & Africa (Process, Workflow, Product, Application, End-Use)
